inhibitors, whereas 6 patients received rituximab. Of these, 2 patients were concurrently treated with cyclophosphamide and corticosteroids, while 2 individuals received cyclophosphamide and corticosteroids after rituximab. After a median follow up time of 29.5 months , median sCr and median eGFR were 1.2 mg/dl (IQR 1.08-2.2) and 52 mL/min/1.73 m 2 (IQR 27-73) respectively. Median proteinuria was 0.94 mg/day . Among patients who received immunosuppressive therapy, one patient did not respond to the treatment, one patient progressed to ESRD two years after diagnosis, whereas partial and complete renal response occurred each in 2 patients. One patient developed small cell lung cancer twelve years after the presentation of the disease. CONCLUSIONS: Fibrillary GN is a rare, though possibly underdiagnosed glomerular disease, with heterogeneity in clinical and histological features and with varying outcomes. Immunosuppressive agents, as well as the anti-B cell depleting antibody rituximab may be an effective treatment that preserves renal function. Further studies are mandatory in order to guide therapeutic decisions.
INTRODUCTION AND AIMS:
As the elderly population is constantly growing worldwide and ageing was associated with senescence of both the kidneys (glomerulosclerosis, interstitial fibrosis) and the immune system (declined immunocompetence), is reasonable to question if patient's age influences the glomerulopathies' outcome. Therefore, a retrospective cohort study was conducted in order to investigate the main predictors of kidney survival in subjects with biopsy-proven glomerulopathies. METHODS: Subjects with a histological diagnosis of glomerulopathy were selected from all native kidney biopsies performed on adults (18 years), in a five-year span (2010) (2011) (2012) (2013) (2014) (2015) , in a single large tertiary care Nephrology center (covering almost 42% of the country population). Repeated biopsies were excluded. Besides the histopathological findings, demographic data (age, gender), and medical information (comorbidities, chronic prescribed medications, urinary protein-to-creatinine ratio -uPCR, estimated glomerular filtration rate by MDRD4 formula -eGFR, microscopic hematuria, routine biochemical parameters) at the time of biopsy were collected from medical records. The time to renal replacement therapy (RRT) initiation was the primary outcome of interest and was obtained from the national Renal Registry database. Only subjects alive at the end of the 5-year follow-up period were retained for the assessment of kidney survival and its predictors by Kaplan-Meier analysis and baseline Cox proportional hazard regression modeling. RESULTS: Overall, 780 subjects with biopsy-proven glomerulopathies were enrolled (59% male, 17.4% 65 years-old). Mean age was 45 (95%CI 43 to 47) and 70 (95%CI 69 to 71) years for the younger and aged groups, respectively. The elderly had lower eGFR (36; 95%CI 29 to 43 vs. 53; 95%CI 49 to 58 mL/min; p<0.001), hematuria (35; 95%CI 20 to 65 vs. 65; 95%CI 50 to 95 per mm 3 ), p¼0.03), serum albumin and hemoglobin, fewer ACE-inhibitors prescription, and higher proteinuria (uPCR 4.7; 95%CI 3.6 to 5.9 vs. 2.4; 95%CI 2.2 to 2.7g/g; p<0.001), inflammation (C reactive protein 20; 95%CI 13 to 27 vs. 13; 95%CI 11 to 15 mg/L; p<0.001), and Charlson comorbidity index (3.1; 95%CI 2.8 to 3.3 vs. 2.4; 95%CI 2.2 to 2.5; p<0.001). Membranous nephropathy, amyloidosis, and crescentic glomerulonephritis were more common, while IgA glomerulonephritis and lupus nephritis were rarer in the elderly (24 vs. 14; 18 vs. 6, 7 vs. 3, 4 vs. 21 , and 4 vs. 11%, respectively p<0.05). RRT initiation was more frequent in the aged subjects (24 vs. 16%; p¼0.02). The kidney survival analysis included 629 subjects (13% 65 years-old) and revealed no need for RRT in 78% of the non-elderly vs. 70% of the elderly (log rank 4.17; p¼0.04). Also, the mean RRT-free survival was shorter in older subjects (55; 95%CI 48 to 61 vs. 61; 95%CI 58 to 62 months; p<0.001). However, multivariate Cox analysis showed only lower serum albumin (expB 0.36; 95%CI 0.23 to 0.55; p<0.001), lower eGFR (expB 0.95; 95%CI 0.94 to 0.96; p<0.001) and the histopathological diagnosis (the worst prognosis for diabetic nephropathy) as independent predictors of the RRT initiation. CONCLUSIONS: Age was not a determinant factor of the kidney survival in this cohort of biopsy-proven glomerulopathies. Therefore, we suggest that the elderly would benefit from the same criteria for the assessment and management of glomerular diseases as younger patients, with appropriate adjustment in drug doses.
SP161 MABTHERA AS RESCUE THERAPY IN RAPIDLY PROGRESSIVE RENAL FAILURE DUE TO RARE IGA DOMINANT MPGN

Luigi Rossi
INTRODUCTION AND AIMS:
Clinical and pathological overlap between IgA Nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) is well known since several years. Ig-positive IgA dominant MPGN is uncommon disease described only as case reports. It affects most often children, patients with alcoholic cirrhosis and a recent report describes it as rapidly progressive renal failure and nephrotic range proteinuria in 55-years-old man needing hemodialysis. Usual treatment is based on long-term steroid therapy, with the possibility of association with other immunosuppressant. We describe the case of 81 year-old patient with IgA dominant MPGN who has been successfully treated with dual Rituximab administration.
METHODS:
We describe the case of 81-years old man hospitalized for fever and acute renal failure. Anamnestically, diabetes mellitus and previous gastric resection for perforated ulcer were reported. At admission, serum Creatinine (sCr) was 4.4 mg/dl, serum Albumin (sAlb) 1.5 g/dl, proteinuria (uProt) 4.9 gr/24h. Other laboratoristic findings were: sieric hypocomplementemia C3 (3 mg/dl), presence of circulating immunocomplexes, monoclonal gammopathy IgMk. We performed a Kidney biopsy that showed on light microscopy a membranoproliferative pattern with IgA and C3 deposits at immunofluorescence (IF). Considering rapidly progressive worsening of renal function and proteinuria, we decide to administer Rituximab 325 mg/m 2 (sCr was 6 mg/dl, uProt 8.6 gr/24 h and sAlb 1.5 g/dl). Ten days later (sCr 3.9 mg/dl, uProt 3.6 gr/24h and sAlb 1.7), we performed second administration. One month after complete therapy, laboratoristic findings were: sCr 1.8 mg/dl, uProt 3.4 gr/24h, sAlb 1.8 g/dl. After another month, sCr 1.5 mg/dl, uProt 2 gr/24h, sAlb 2.2 g/dl. RESULTS: In this case, the patient had a rapidly progressive renal failure. Laboratoristic and histological findings confirm activation of classical complement pathway, lead us towards diagnosis of IgA dominant form of MPGN. Considering worsen of renal function and patient co-morbidities, we decided to administer Rituximab as rescue therapy, plus low dose of steroid (Prednisone 10 mg/die). Literature review shows that patients with MPGN due to a monoclonal gammopathy should undergo Rituximab treatment to attain remission of the hematologic dyscrasia. Moreover, recent evidences suggest that patients with MPGN associated with monoclonal immunoglobulin deposits and no overt hematologic cancer, had a good response to Rituximab, too. So we administered two 325 mg/m 2 doses of Rituximab at ten dayinterval. Rapid response to therapy confirm the presence of unusual form of MPGN and highlights importance of Rituximab as rescue therapy . CONCLUSIONS: To the best of our knowledge, this is the first report of Rituximab administration to treat IgA dominant MPGN. Our therapeutic approach was quickly effective and devoid of any side-effects. 
